CCCC (C4 Therapeutics Inc) Earnings per share for the last four quarters

Public company logo of C4 Therapeutics Inc (CCCC)

The asset value tracked on the GURU.Markets chart, which currently stands at 57.00, refers to C4 Therapeutics, Inc. (CCCC), a biotech firm that developed the TORPEDO system for the complete degradation of harmful proteins via oral delivery. C4 Therapeutics, Inc. (CCCC) relies on collaborations with global pharma behemoths to bring new molecules to market. The brand's high authority among physicians confirms its success in combating severe forms of oncology.

CCCC c4therapeutics.com Earnings per share for the last twelve months (02/11/2024 - 11/17/2026)

C4 Therapeutics Inc - analytical breakdowns and key metrics (CCCC)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:C4 Therapeutics (CCCC)
Signature product of C4 Therapeutics

C4 Therapeutics, Inc. (CCCC) invests in a highly skilled staff of chemists to develop targeted protein degradation methods. The rolling trailing twelve-month (TTM) earnings per share (EPS) trend measures the rate of change in net income, adjusted for one-time items. This indicator allows for an assessment of the efficiency of R&D cost management and RSU packages amid inflationary pressures. By analyzing historical year-over-year EPS growth (TTM), an investor determines the sustainability of the business's profitability.

Competitor analysis for C4 Therapeutics, Inc.

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (immuneering.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX